PHVS
Pharvaris NV

901
Mkt Cap
$1.52B
Volume
99,287.00
52W High
$29.80
52W Low
$11.51
PE Ratio
-7.36
PHVS Fundamentals
Price
$23.87
Prev Close
$23.68
Open
$23.56
50D MA
$23.73
Beta
0.60
Avg. Volume
328,583.74
EPS (Annual)
-$2.69
P/B
4.19
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America
Bank of America increased their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company a "neutral" rating in a research note on Thursday...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America
Bank of America increased their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company a "neutral" rating in a research note on Thursday...
MarketBeat·6d ago
News Placeholder
Pharvaris (NASDAQ:PHVS) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a research report on Wednesday...
MarketBeat·7d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
News Placeholder
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
News Placeholder
Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Should You Buy?
Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Here's What Happened...
MarketBeat·7d ago
News Placeholder
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment
The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks.
Stocktwits·8d ago
News Placeholder
Pharvaris (NASDAQ:PHVS) Sets New 1-Year High - What's Next?
Pharvaris (NASDAQ:PHVS) Sets New 52-Week High - Here's Why...
MarketBeat·13d ago

Latest PHVS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.